Showing results (171-180 of 290) with videos related to
Sort By:
Pageof 29
Cancer Discovery|August 20, 2015
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to AfatinibJean-Nicolas Gallant, Jonathan H Sheehan, Timothy M Shaver, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2018
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase InhibitorsAlexa B Schrock, Viola W Zhu, Wen-Son Hsieh, et al.BJU International|January 28, 2020
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertionsRussell W Madison, Sumati V Gupta, Yasir Y Elamin, et al.European Urology|February 21, 2016
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic AlterationsGabriel G Malouf, Siraj M Ali, Kai Wang, et al.Cancer|January 17, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3Jeffrey S Ross, Marwan Fakih, Siraj M Ali, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR geneNaiyer A Rizvi, Valerie Rusch, William Pao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancerGregory J Riely, Naiyer A Rizvi, Mark G Kris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.Cancer Discovery|September 8, 2012
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutationKen Takezawa, Valentina Pirazzoli, Maria E Arcila, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.Pageof 29